At 10.7, the P/E for Abbott Laboratories (NYSE:ABT) is higher than six of the nine large pharmas that derive 78% or more of their total revenues from sales of prescription drugs. Novo Nordisk A/S (CSE:NVO; NYSE:NVO) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), with P/Es above 13, have